Navigation Links
Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
Date:1/26/2009

> isolates were 0.06, 0.12, and 4 micrograms/mL, respectively. Delafloxacin's MIC90 values against all MRSA including the quinolone-resistant MRSA strains was also 0.06 micrograms/mL.

"We are extremely encouraged by the final results of this third Phase 2 trial, which affirm delafloxacin's safety and show its broad spectrum activity in difficult-to-treat complicated skin infections," said Susan Froshauer, Ph.D., President and CEO of Rib-X Pharmaceuticals. "Delafloxacin proved to be the more active compound compared to tigecycline when evaluated against both Gram-positive and Gram-negative bacterial isolates from patients, including MRSA and quinolone-resistant MRSA and other organisms. Additionally, this drug has the potential for IV use in the hospital with an oral step down."

"Rib-X starts off 2009 extremely well positioned to proceed with advancing delafloxacin towards Phase 3 trials," continued Dr. Froshauer. "We not only have excellent Phase 2 results for one of our key compounds, but we also have the commitment of our investors, and we would like to thank them for their continued support."

Phase 2 Study Design and Results

This Phase 2 double-blind study evaluated the safety and efficacy of delafloxacin at two intravenous doses, 300 mg BID and 450 mg BID, compared to tigecycline (TYGACIL(R), Wyeth Pharmaceuticals), in adults with cSSSI. Treatment duration was 5 to 14 days. Of the 150 patients randomized in this trial, 68% were male; the mean age was 40+/-14.5 years. 36% had cellulitis, 31% had wound infections and 33% had abscesses. 111 (74%) patients had pathogens identified at baseline, with 96 identified as S. aureus.

The clinical cure rates in the Clinically Evaluable and Modified Intent-to-Treat populations are presented below:

                       Percent Clinical Cure at TOC
    Population      DFX 300 mg BID      DFX 450 m
'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
2. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
3. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
4. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
5. MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
6. Axikin Pharmaceuticals Spins out of Actimis
7. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
8. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Cumberland Pharmaceuticals Appoints Lee Product Director
10. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
11. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asian ... in Asian with analysis and forecast of revenue. The ... grow to around $463.9 million by 2018, at a ... Browse through the TOC of the Asian Automatic patient ... analysis provided. This also provides a glimpse of the ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems report ... and forecast of revenue. The Orthopedic braces and support systems ... million by 2018, at a developing CAGR of 4.4% from ... Asian Orthopedic braces and support systems market, to get an ... glimpse of the segmentation of orthopedic braces and support systems ...
(Date:10/18/2014)... 2014 The “Human Insulin Market- ... Acting, Premixed), Modern Human Insulin (Rapid Acting, Long ... Novomix, Tresiba, Others) - Forecast to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:10/18/2014)... The Asian arthroscopic devices report defines ... and forecast of revenue. The arthroscopic devices market in ... 2018, at a CAGR of 6.5% from 2013 to ... arthroscopic devices market, to get an idea of the ... the segmentation of arthroscopic devices market in the same ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4
... - - ... -, SOUTH SAN FRANCISCO, Calif., Aug. 17 ... U.S. Food and Drug,Administration (FDA) has approved Zingo(TM) (lidocaine ... analgesia to reduce the pain associated with venous access,procedures, ...
... (Nasdaq: IDEV ) today announced that it ... and Drug Administration (FDA) for,VALSTAR(R). VALSTAR, a sterile ... product approved by the FDA for therapy of,bacillus ... bladder. VALSTAR was removed from the market ...
... Union announced today they,have entered into a five-year ... in Region 3 to provide RealTime1(TM) (RT1(TM)),software at ... and the,US Virgin Islands. The Region 3 Genetics ... funding for another five-year period.,With this renewal, Region ...
Cached Biology Technology:Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 2Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 3Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 4Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 5Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4Digital Union's RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative 2
(Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
(Date:10/17/2014)... news release is available in German . ... millions of sperms every day in order to reproduce? And ... are the topic of the latest issue of the research ... 2014). The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld ... it is not unusual for a female to copulate with ...
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... genes can reveal not only the "lifestyle" of marine microbes ... finding means researchers may be able to predict the types ... the genomes of just a few dominant species, according to ... Wales. As well, it may reveal new insights into the ...
... removed during liposuction conceal versatile cells that are more ... cells, or iPS cells, than are the skin cells ... study from Stanford,s School of Medicine. "We,ve identified a ... of the research, Michael Longaker, MD, who has called ...
... for 50 percent of the fish consumed globally, according to ... while the industry is more efficient than ever, it is ... large amounts of feed made from wild fish harvested from ... the Sept. 7 online edition of the Proceedings of ...
Cached Biology News:Genomes reveal bacterial lifestyles: Research 2'Liposuction leftovers' easily converted to IPS cells, Stanford study shows 2'Liposuction leftovers' easily converted to IPS cells, Stanford study shows 3Half of the fish consumed globally is now raised on farms, study finds 2Half of the fish consumed globally is now raised on farms, study finds 3
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Sprague Dawley rats, 7-8 weeks of age, mixed gender; collected by exsanguination in Alsever's solution at 1:2 dilution...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... BAC (100+kb), fosmid (40kb), and large plasmid ... any othe BAC vector. On command 20-50 ... easy recombinant DNA purification. Available with blue-white ... vectors for the highest insert stability. Kits ...
Biology Products: